Blowing the Whistle at the FDA, Jan 2001, exposing Dearborn and how OspA causes immunosuppression rather than, "was a vaccine."

01 Oct 2017


File List, RICO

1988 Steere says Lyme is like a B cell leukemia

Assoc Blogs-n-Webs:




Fungal Exosomes Inhibit Apoptosis

IDSA: "Vaccines serve the mfgs, not their victims"


BlumenthalAntiTrust Lawsuit

Exosomes, Blebs


CDC Admits Fraud, 2016
Dattwyler, 1988
Golightly, 1988
Dressler, 1994
BarbourFish, 1993
Dearborn, 1994

Pathogenic Fungi

Bush's warcrimes, Oct 2000





141113 The Lyme Vaccine Scam, Facebook "Occupy the USDOJ" Group version

You need to study this information in order to file your Adverse Event (AE) to the Dearborn Lyme case definition to the Food and Drug Administration.  Hopefully, when this cryme is prosecuted you can be compensated by the USDOJ in a similar manner to the other Vaccine Injury Compensation cases the USDOJ handles.  THAT is our ultimate goal.

Here is the FDA's AE reporting form re bogus medical testing:

You need to study this report (in this yellow box) as well as the Primers Shell Game in order to see why you only ever needed antibody band 41 and the triad of Neurological, Cognitive, and Musculoskeletal signs after ruling out cancer, etc. for a diagnosis of borreliosis.

And if you already know about this cryme and are still wondering why the US "government" is so friggin stupid and incompetent, don't.  They just are.  It goes with the territory of government-employee-cults and government-employee union-cults.  Read about cults - they just protect themselves, their retirement funds and investments, and each other, you know, like cops.

First let’s examine the following 7 compelling reports from the “20 Reports that show the Lyme-and-LYMErix-Post-Sepsis Cover-up has to do with Hiding Autism Brain Damage from Vaccines
( );”

These next 7 reports are basically by the NIH, especially the NINDS’s Lyme-And-MS group (Martin and Marques) which confirm and endorse the idea that the Lyme vaccine (OspA, which is a basic Pam3Cys molecule type and a TLR2/1-agonist) gave people the same New Great Imitator and especially Multiple Sclerosis outcomes as “Chronic Lyme” or Late Neurologic Lyme;

These reports are from the NIH, IDSA, the US ARMY, Ft. Detrick, the National Cancer Institute (NCI), and Washington University, St. Louis, MO ( about post-sepsis and the reactivation of the herpesviruses, et al (like AIDS) from exposure to Lyme. [This is how it appears anyway. If it is some other virus like a mouse herpesvirus from a tick bite, we don’t have that data yet. It’s something like that, that obviously no one at the Uncle Sam “government” seems too worried about, therefore, it must be a common thing like from the herpes family. There are easily 20 million of us with a CFIDS, Lyme, or Fibromyalgia etc junk-science diagnosis in America alone (NIH’s own published stats) and no one’s panicking like we got a new, slow Marburg, or contagious scrapie, or a new HIV or whatever going on.]

==================== The 7 Reports, 6 of NIH’s plus’s =================

1989 (this is in IDSA's own journal):
NCI and US Army Ft Detrick Pathologist Paul Duray on the CSF cells looking like "Epstein-Barr-like transformed cells" in IDSA's 1989 Reviews Supplement on Spirochetal Diseases:
Rev Infect Dis. 1989 Sep-Oct;11 Suppl 6:S1487-93.
Clinical pathologic correlations of Lyme disease.

"Immature B cells can also be seen in the spinal fluid. These cells can appear quite atypical- not unlike those of transformed or neoplastic lymphocytes." -- 

Full Text:



Duray again in 1992, in Steve Schutzer's review of the 1992 Cold Spring Harbor Conference on Lyme:

"On occasion, these atypical-appearing large lymphocytes have been misinterpreted in biopsy by several laboratories as cells of a malignant lymphoma or leukemia. Bb antigens, then, may stimulate growth of immature lymphocytic suibsets in some target organs, as well as in the cerebrospinal fluid (Szyfelbein and Ross 1988). Usual bacterial infections do not produce such lymphocytic infiltrates in tissue. ****These immunoblastoid cells in Bb infections at times resemble those found in Epstein-Barr virus infections.**** Does Bb reactivate latent virus infections in tissues? Do some tick inocula harbor simultaneous infectious agents (ixodid ticks can harbor Rickettsiae, Babesia microti, and Ehrlichia bacteria, in addition to Bb), producing multi-agent infections in some hosts? Further studies can clarify these issues by mans of tissue-based molecular probe analysis." -

Paul Duray, NCI, NIH, Ft. Detrick, at the 1992 Cold Spring Harbor Crooks' Conference, published in Steve Schutzer's Lyme Disease: Molecular and Immunologic Approaches. - book.



The NIH (NINDS’s MS-Lyme Group) group that discovered that *** OspA *** was the cause of the MS/New Great Imitator outcome of Lyme reporting in the New York Times in the summer of 2013 (Martin and Marques, 2006);
this article says these OspA like antigens constantly shed by Borreliae cause immunosuppression in the humoral immune system, but apparently a chronic inflammatory state in the central nervous system:

"Borrelia burgdorferi Induces TLR1 and TLR2 in human microglia and peripheral blood monocytes but differentially regulates HLA-class II expression."

and this report means you might not even have anti-flagellar antibodies (flagellin is a TLR5-agonist) after being exposed to shed fungal OspA like antigens (TLR2/1-agonists):

"Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes.

2013 - Same NIH MS-Lyme Group as above, Martin and Marques:

"When Lyme Disease Lasts and Lasts" – Jane Brody

"Complicating the picture is the fact that some people with PTLDS symptoms apparently never had Lyme disease in the first place, Dr. Marques said in an interview. There are other infectious organisms — Epstein-Barr virus, for example — that can produce similar symptoms and may be the real culprits."


2014: discovers that sepsis is like Lyme, in that the survivors of it are likely to have survived via the immunosuppression (TLR2-agonist tolerance/Endotoxin tolerance), but the result is the reactivation of latent viruses:

"Dormant viruses re-emerge in patients with lingering sepsis, signaling immune suppression"

"Patients with lingering sepsis had markedly higher levels of viruses detectable in the blood, compared with the healthy controls and critically ill patients without sepsis. Among the sepsis patients, for example, the researchers found that 53 percent had Epstein-Barr virus, 24 percent had cytomegalovirus, 14 percent had herpes-simplex virus, and 10 percent had human herpes simplex virus-7.

"These viruses generally don’t lead to significant illness in people who are healthy but can cause problems in patients who are immune-suppressed. "


Reactivation of Multiple Viruses in Patients with Sepsis

“Sepsis is the host's non-resolving inflammatory response to infection that leads to organ dysfunction [1], [2]. A current controversial hypothesis postulates that if sepsis pursues a protracted course, it progresses from an initial primarily hyper-inflammatory phase to a predominantly immunosuppressive state [3]–[7]. Experimental therapeutic approaches in sepsis have almost exclusively focused on blocking early inflammation or host-pathogen interaction and failed [8]–[10]. Recently, immuno-adjuvant therapies that boost host immunity, e.g., GM-CSF and interferon-γ, have been successful in small clinical trials thereby supporting the concept that reversing immunosuppression in sepsis is a plausible strategy to improve outcome [11], [12]. However, several issues have limited this approach including lack of consensus that immunosuppression is a clinically important phenomenon [5], [6], [13]. Also, difficulty in identifying patients with impaired immunity as well as determining optimal timing for administration pose significant challenges to pursuing this approach [14]. While immuno-adjuvant therapies might improve sepsis survival if administered during the later immunosuppressive phase, these agents might worsen outcome if given during the early hyper-inflammatory phase [4], [14]. Thus, a means to distinguish these two contrasting phases of sepsis is needed not only to verify the hypothesis that sepsis progresses to an immunosuppressive state but also to guide use of potential agents which boost immunity.

“Latent viruses such as cytomegalovirus are normally held in abeyance by cellular and immune surveillance mechanisms which if impaired, for example by immunosuppressive medications, often result in viral reactivation, replication, and virally-mediated tissue injury [15]–[20]. Sepsis impairs innate and adaptive immunity by multiple mechanisms including apoptosis-induced depletion of immune effector cells and induction of T-cell exhaustion thereby possibly predisposing to viral reactivation and dissemination [21]–[23]. …” 


2014, Here the NIH confirms that they agree that post-sepsis, like wustl above describes, matches their own observations of what happens as a result of Chronic Lyme (EBV reactivated; ie, that being generally accepted as the main driver of MS and Lupus):

NEW, by the NIH: "Surviving Sepsis: Detection and Treatment Advances"

By Carolyn Beans for the National Institutes of Health | August 18, 2014 08:43am ET

"Preventing Secondary Infections

"Some people who survive sepsis can develop secondary infections days or even months later. A research team that included Richard Hotchkiss, Jonathan Green and Gregory Storch of Washington University School of Medicine in St. Louis suspected that this is because sepsis might cause lasting damage to the immune system. To test this hypothesis, the scientists compared viral activation in people with sepsis, other critically ill people and healthy individuals. The researchers looked for viruses like Epstein-Barr and herpes simplex that are often dormant in healthy people but can reactivate in those with suppressed immune systems. [Sepsis Has Long-Term Impact for Older Adults, Study Finds]"

======================== End 7 Reports =================


So, that data, those 7 reports are hard to argue with, and they also point to someone else potentially hypothesizing on what the treatment is for post-Lyme-post-sepsis, like wustl or the NIH and not me ☺

Importantly, everyone should go to PubMed and look at the data on medical school students and astronauts and see how the stress hormone cortisol is well-known to be activating mono or Epstein-Barr. If you are an astronaut or a medical school student or overworked resident, your chronic fatiguing disease is allowed to be real and not somatoformically produced with your magical brain ☺

Let's side step to show that LYMErix or OspA and OspA-like antigens constantly shed by borrelia in an immune-evasion-come-antigenic variation mechanism that can leave the immune system "completely overwhelmed," even if a mammal was infected with just one spirochete (see the Primers Shell Game).  We all have to know what these fungal OspA etc antigens are, that are shed by borreliae such that we know the pathology it causes.  OspA is or Pam3Cys or tripalmitoyl cysteine molecular type (see that this is confirmed by Ray Dattwyler in the "20 Reports that show the link between Lyme Cryme and Autism").  We have to know what these antigens are in order to know what they do (structure predicts function).  So, if you can't determine the structure, you can go by their function or biochemical properties and in this case, Pam3Cys type antigens are managed by TLR2/1 and that means they are fungal.
So what happens when the body is hyperexposed to fungal antigens?  In most cases, immunosuppression as shown by Justin Radolf and Clifford V. Harding, here, in the Plum Island chapter of Cryme Disease.  They cause the HLA molecules to fail to present antigen and thus, no more antibodies are made.  This is called tolerance.  Use PubMed to examine further what people like Medvedev and Harding have to say about what happens to the immune system after chronic exposure to fungal antigens.  Note in parallel, the data on the NO-TB-VACCINES, duh.  The Lyme criminals were too stupid to even try to discover if there had been any successful lipoprotein vaccines in the past.

Use 141114_FUNGAL_FAILED_VACCINES.htm for about 12 reports that show you can't use this molecule type for a vaccine and that the Lyme criminals never gave a shit what it was or if it had been tried before as a vaccine.



Returning to what happened with LYMErix - the vaccine that gave people the very disease the ALDF-come-IDSA now deny exists and wrote out of the Dearborn serodiagnostic criteria specifically because of that ☺

[Repeat: The definitions of Lyme borreliosis excluded from the Dearborn case definition (falsified by Allen Steere in Europe in 1992) are the very ones caused by OspA vaccination. You just saw how in the above 7 reports, and there is much more data on that available on PubMed about the pathologies caused by chronic exposure to fungal antigens including cancer, and the similar outcomes of worse disease and immunosuppression from other experiments with fungal vaccines of this same TLR2/1 agonist type such as all the failed Tuberculosis vaccines ☺ ]


We back up to what was the original case definition serology the CDC published in 1990 such that we know it was falsified at Dearborn, and this data jives with what we know from the 7 reports by the NIH above:

1986, Allen Steere says:
“Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness.

“Using immunoblots, we identified proteins of Borrelia burgdorferi bound by IgM and IgG antibodies during Lyme disease. In 12 patients with early disease alone, both the IgM and IgG responses were restricted primarily to a 41-kD antigen. This limited response disappeared within several months. In contrast, among six patients with prolonged illness, the IgM response to the 41-kD protein sometimes persisted for months to years, and late in the illness during arthritis, a new IgM response sometimes developed to a 34-kD component of the organism. The IgG response in these patients appeared in a characteristic sequential pattern over months to years to as many as 11 spirochetal antigens. The appearance of a new IgM response and the expansion of the IgG response late in the illness, and the lack of such responses in patients with early disease alone, suggest that B. burgdorferi remains alive throughout the illness.”

1990, CDC publishes this case definition:

The 1990 case definition standard (above) was basically based on the 1986 report (above that) by Allen Steere, which was that you have to merely show a person has a Relapsing Fever infection, with the “new IgM and changing bands emerging over time seen in repeat or serial Western Blots.” That meant, according to Allen Steere, “the bug is still alive.” New, IgM type bands meant the bug was still alive and you have not killed it with antibiotics. Steere also wrote in that same report that really all you need is band 41 to diagnose Lyme, just rule out Syphilis. That is important to remember. You only need band 41or the anti-flagellar antibody and the triad of symptoms to diagnose Lyme. The US patent 5,618,533 specific recombinant fragment of Borrelia burgdorferi flagellin of Yale’s is a better test and is an actual FDA-validation according to their criteria (as shown in the Primers Shell Game chapter of Cryme Disease).

I personally – and I am not a doctor – recommend everyone rule out all blood cancers since the symptoms of Chronic Lymphocytic Leukemia for example are identical to Chronic Lyme or MS, not to mention the fact that Lyme and LYMErix both are known to cause cancer as are the mycoplasma to which chronic late neurologic Lyme victims now are tolerized to (fungal).


And what is the current, 1994 CDC Dearborn case definition?

“It was recommended that an IgM immunoblot be considered positive if two of the following three bands are present: 24 kDa (OspC) * , 39 kDa (BmpA), and 41 kDa (Fla) (1).
“It was further recommended that an that IgG immunoblot be considered positive if five of the following 10 bands are present: 18 kDa, 21 kDa (OspC) *, 28 kDa, 30 kDa, 39 kDa (BmpA), 41 kDa (Fla), 45 kDa, 58 kDa (not GroEL), 66 kDa, and 93 kDa (2).”


That is very different criteria from the first criteria. First you only needed band 41, or test using repeat Western Blots to look for new IgM bands since Lyme is a relapsing fever organism, and the nature of the relapse is antigenic variation (producing new antigen and thus new IgM bands will be produced in a human), … and now all of a sudden you have to have all these bands showing up at once (indicative only of the hypersensitivity, HLA-linked response) and just ignore IgM bands, basically.

You can assume that the reason the IDSA/ALDF/CDC/Yale Lyme criminals do not want anyone treated for Lyme is because late in the disease it’s really about fungal antigen tolerance and cross tolerance, as well as reactivated herpesviruses. They don’t want Lyme victims being treated with antibiotics because that might help transfer antibiotic resistance genes between all the OTHER infections we have, like fungal, like Tuberculosis, Chlamydia, Candida, and whatever else … for which we are now carriers, … and you don’t treat the herpesviruses and subsequent B cell mutations with antibiotics. likes to say what diseases are not, but they never say what diseases are. It’s pretty strange but we got no Einsteins in that bunch. IDSA be like… an incomplete sentence. They’d be good screenwriters for American soap operas. The rest of MD-America does not even notice that IDSA’s is one funny script, even after these crooks lost their “vaccine,” Senator Richard Blumenthal (a former USDOJ prosecutor) sued them for Anti-Trust, and Edward McSweegan became America’s infamous NIH employee and America’s one and only “Man With No Work.”


So, Follow: First, Lyme was a regular old Relapsing Fever organism and a “New Great Imitator!” Later, it at the same time the crooks had a vaccine candidate in early phase trials, become nothing and a non-disease. We were then about to get “a vaccine for a disease that causes no illness.” That is still the current position of Yale, CDC, IDSA, and the ALDF/EUCALB. “Lyme patients are not sick, and OspA was a vaccine.” IDSA still makes that claim today. No one in the AMA or Mass Medical Society or NEJM or any other association or society of “doctors” even blinks at these contradictory notions. To me it looks like a case of Kraepelinian split-brain. We should wonder what other evidence there might be that medical school is a cult that produces schizophrenia.


Here is basically of the series of events that occurred in the process of redefining Lyme as a non-disease to pass off a bogus vaccine:


1986, Edward McSweegan trashes U.S. Navy for $$$ for his psycho buddies at the cabal in a letter to Senator Barry Goldwater. See the Navy’s furious response. Sweeg thinks there can be a vaccine for Relapsing Fever, confirming the paraphysical theory that arrogance is the seed corn or germinal element in true, genuine stupidity and/or the development of a criminal mind.

1988, Raymond Dattwyler & immune-suppressing, seronegative Lyme; supernatant (lipid layer) of borrelia mash causes NK cell anergy or a blunted immune response. Later Dattwyler tells the FDA Vaccine committee that the seronegative patients are the sickest (now we know why, as shown above where Lyme and LYMErix are the Great Detonators of the latent herpesviruses and expanded or cross tolerance to other than TLR2/1-agonist bearing antigens; in short, they’re double-fatigued and neurologically damaged):

1990, CDC: "Diagnose Lyme as if it was Relapsing Fever."

1990, Allen Steere reports that "NeuroLyme won't test positive," uses Dattwyler and Volkman’s Seronegative Lyme T Cell Assay

Says Steere:

“If the patient was seronegative according to these methods, the serum was further tested by immunoblotting (25) and peripheral blood mononuclear cells were tested for reactivity with borrelial antigens by proliferative assay.(26)"

And what was reference number 26?


Pretty amazing, huh?

1990, founded, self- proclaimed “entrepreneurial quartet” is McSweegan, Fish, Wormser and Connolly. (You will want to look at who are their sponsors and on their board, seriously.)


1992, CDC officer Allen Steere falsifies testing in Europe:
The PubMed links to those 2 reports – no full text available, that is why I got them out of the Yale Medical Library in 2002 and scanned them in are:
“Antibody responses to the three genomic groups of Borrelia burgdorferi in European Lyme borreliosis.”
“Western blotting in the serodiagnosis of Lyme disease.”

Of those 2 reports of Steere’s shenanigans in Europe, only the second one is made a part of CDC’s Dearborn booklet but the first one is where you can see how he falsified the testing.

Steere in Europe used bogus high passage strains that drop plasmids helping leave OspA and B out of the diagnostic standard  (by using the recombinant protein end only- you need the lipids to be immune stimulatory) for his later monopoly on post-LYMErix-approval North America, with Corixa, Yale’s L2 Diagnostics and Imugen, officially listed on the Securities and Exchange Commission (SEC) as “partners” in sharing licensing of the RICO Monopoly patent with the strain of Borrelia that had dropped an OspA-B plasmid US Patent 6,045,804 (we will come to this later, it is critical to the whole scam and shows the intent of their entire enterprise);

Here is a transcript of what is in the first report on exactly how Steere defrauded Uncle Sam:

“The group 1 strain of B. burgdorferi, G39/40, used in this study and in the previous study of US patients was isolated from an Ixodes damini tick in Guilford, Connecticut [21]. The group 2 strain, FRG [Federal Republic of Germany], was isolated from Ixodes ricinus near Cologne [22]. The group 3 strain, IP3, was isolated from Ixodes persulcatus near Leningrad [23]. All three strains used in this study were high passage isolates, which were classified by Richard Marconi (Rocky Mountain Laboratory, Hamilton, MT) using 16S ribosomal RNA sequence determination as described [11, 24]. The recombinant preparations of OspA and OspB used in this study were purified maltose- binding protein-Osp fusion proteins derived from group 1 strain B31 [25]. The fusion proteins contained the full-length OspA or OspB sequence without the lipid moiety or the signal sequence -"

Here is what it says in the Persing/Schoen/Steere or Imugen RICO Monopoly patent, that shows the intended monopoly:

“Method for detecting B. burgdorferi infection”

"Additional uncertainty may arise if the vaccines are not completely protective; vaccinated patients with multisystem complaints characteristic of later presentations of Lyme disease may be difficult to distinguish from patients with vaccine failure."

"The present invention provides a method useful to detect a B. burgdorferi infection in a subject. The method provided by the invention is particularly useful to discriminate B. burgdorferi infection from OspA vaccination, although it is sufficiently sensitive and specific to use in any general Lyme disease screening or diagnostic application. Thus, the method of the invention is particularly appropriate for large scale screening or diagnostic applications where only part of the subject population has been vaccinated or where the vaccination status of the population is unknown. "

The monopoly on post-LYMErix-FDA-approval testing for all vector borne diseases in America and Canada was their stated intention.  Once LYMErix was on the market, you had to use a strain of borrelia that did not have the vaccine antigens in them, because you never test for vaccine efficacy with the very same antigen as the vaccine antigen (you would not know if the person has the actual virus or whatever, or that antibody came from the vaccine). So, their monopoly depended on LYMErix being on the market.  That way, Corixa, L2 Diagnostics and Imugen would be the only labs in the country licensed to use this RICO strain.  They, at the same time would have access to all the human blood to pharm all sorts of DNA data from humans as well as any new and emerging infectious diseases... meaning even more vaccine patents. 

So, they falsified the case definition to leave out neurologic Lyme cases, and they left OspA and B out for a later monopoly on testing and future patents.  And there, you just read that in a patent developed by Schoen and Persing in 1995.

1992, CDC staff, Barbara Johnson and Joe Piesman, own patents with SmithKline that show 2 kinds of Lyme, HLA-linked and non-HLA-linked antigens:

“Summary of the Invention
“In one aspect, the invention provides isolated --B. burgdorferi antigens which are regulated and differentiated by growth of the B. burdorferi in a tick vector. Novel antigens of the invention are listed below in Table I.

“Certain of these antigens are characterized as being B. burgdorferi B31 strain specific and major histocompatibility complex (MHC) nonrestricted. Certain other of these antigens are characterized as being MHC-restricted.”


So, what the hell is the CDC talking about ”MHC-restricted and MHC non-restricted?” What we know that to mean is for instance, classic autoimmune diseases tend to be MHC-restricted, or the antigens, due to intermolecular forces, bind in the HLA groove too strongly causing a hypersensitivity response. That is the new definition Steere claimed in these 1992 reports and at the CDC’s 1994 Dearborn conference.
The very re-definition of “Lyme Disease” at Dearborn became “HLA-restricted,” “just the arthritis,” “too-many-antibodies-HLA-associated response.” In short, Steere and the CDC claim Lyme Disease is just an HLA-restricted disease. Here in their 5 1992 patents with SmithKline, the CDC mentions the other outcome? The no- or fewer antibody result?

1993, Barbour and Fish slam Neurologic Lyme victims:
The SOCIAL Phenomenon of Lyme Disease or what the hell ever… where they admit Phase I and Phase II trials of OspA vaccines are underway. Therefore, as is shown in the Persing RICO Monopoly patent from 1995 shown and linked above (US 6,045,804), they already knew the OspA vaccines were causing a disease indistinguishable from vaccine failure, or CHRONIC LYME:


Compare the 2 kinds of Lyme in the RICO complaint filed with the USDOJ in July 2003– compare the blots. On the left is neurological Lyme (the sickest, according to Ray Dattwyler) and on the right is the HLA-linked outcomes of arthritis and acrodermatitis:


So, these assholes left out the left-sided, neurological outcomes in their Dearborn scam. The whole point of the redefinition of Lyme at Dearborn was to narrow it to just the HLA-linked hypersensitivity cases. This is how and why they get away with perjury. When the IDSA/Yale Lyme crooks say “Lyme Disease” that means HLA-linked arthritis AND NO OTHER SYMPTOMS.


Here next, in 2005, Klempner and Wormser re-revealed that “Lyme Disease” is just one thing. There are 2 things, and the controversial thing really does not have a name right now, but “Lyme Disease” is JUST a bad knee and no other illness signs. THAT is the definition. It’s a legal one and a criminal one, and based on bullshit and no consensus, but here is what it is again (2005):

“A Case-Control Study to Examine HLA Haplotype Associations in Patients with Posttreatment Chronic Lyme Disease”


People with ONLY the HLA-linked arthritis (the falsified Dearborn case definition)…“Patients generally feel well aside from their arthritis symptoms,” Say Wormser and Klempner. Pretty amazing right? That the people with the falsified Dearborn case definition of “only an HLA-linked arthritis in a knee” have only an HLA-linked arthritis in a knee and no other symptoms?

I love it when that happens ☺
You falsify the case definition and say “ONLY the HLA-linked hypersensitivity response can be a ‘case’ of ‘Lyme Disease,’" and then 11 years later say, “Oh, how amazing for us to find only the HLA-linked case definition is HLA-linked and is only a bad knee. Maybe someone can promote me to the head of a CDC bioweapons lab in Boston on accountta my astuteness.”


1994, June FDA LYMErix Meeting (note that June precedes October, so the FDA never approved of the Dearborn method, not to mention it was research fraud and not a consensus):

Transcript of June 1994 FDA Meeting Minutes:

“So, individuals with a poor immune response tend to have worse disease.”


We know why now ☺ Borrelial fungal antigens cause immunosuppression and… a classic “post-sepsis” like result with chronic active EBV, et al.


The CDC recently made a big ta-do over the Blumenthal et al letter to the Office of Policy and Management, where the Senators are forcing the FDA to do their jobs and assure that the testing for Lyme is validated according to their own FDA rules (See the Primers Shell Game for more on that). The CDC is trying to say the Dearborn method was FDA validated.

False. The FDA had nothing to do with the Dearborn stunt.

1994, CDC's invitation to participate in Dearborn .pdf   Labs were invited, they said the Steere proposal sucked, CDC blew off these labs recommendations:


1994, October CDC's Dearborn Booklet .pdf


Dearborn, Who Said What?

1) Gary Wormser at New York Medical College reports that Steere’s Dearborn proposal method detected 9/59 of IgG cases (which, most very sick people being detected too late are obviously not going to have this Early Lyme profile, especially considering Steere’s Late Lyme Arthritis Dearborn falsified definition was intended to be for early Lyme, regardless of his lab shenanigans with the strains and the phony recombinant OspA and B in Europe):
Serodiagnosis in Early Lyme Disease


So, Wormser says only 9 of the 59 meet Steere’s Late Lyme Arthritis case definition. That’s 15% accurate.

2) Igenex- Steere’s IgG detected 8% of the cases

3) Imugen – Steere’s method detected 14% of the cases:

4) Wisconsin - Steere’s method was 15% accurate

5) UCONN- Larry Zemel was referring to Lyme as comparable to juvenile rheumatoid arthritis. Recommended adding band 50 for children’s blots.

6) Roche—28% were positive for 5 of 10 Steere IgG bands.

7) Wadsworth – had some different scoring system. Did not report on accuracy of Steere

8) Ontario Ministry of Health

9) Lutheran Hospital— 22 % were accurate by Steere’s IgG

10) MarDx Labs – recommended adding bands 31 and 34, but were given CDC positive arthritis positive blood to falsely qualify their test strips. Theirs were used in both vaccine trials. MarDx was later sold to an Irish company, Trinity Biotech, Dublin, so presumably all they know about the crime was taken out of the country.

11) CDC Atlanta – talked about mice, not humans. The mouse criteria was 2 out of three from OspC, 16 kD, 17.9 kD, for the mice. Wonderful. Everyone is concerned about Western Blotting the poor little mice. Such a tragedy that they have to run around sick. We read about this tragedy at least once a week in the New York Times. People say each other all the time, “Oh, what wonderful weather we’re having, too bad the mice are too sick with Lyme Disease to enjoy it. “ You see those little collection tins at all the supermarket check-outs: “Please Donate One Dollar for the Poor Mice with Lyme Disease!”


So, we got this standard anyway, even though none of the invited participants agreed - not by a long shot.  See the Primers Shell Game reports here or at this link:
for an explanation of how VALID testing is performed according to the FDA rules and how Yale knows all about how to validate a method, validated one (Bb specific flagellar antigen) and patented it (US 5,618,533).  So that's all obvious criminal fraud.

Who was involved with approving the bogus Dearborn method at Dearborn when all the invited labs said it sucked??  Why, none other than the CDC vaccine patent  owners and all the scammers you see here:

Alan Barbour, Edward McSweegan, Allen Steere. Arthur Weinstein, "The CDC Lyme Disease Group" (Barbara Johnson)

Kind of amazing. The same people involved in the OspA vaccines scam were involved in falsifying the testing.


Igenex, Harris’ view of the Dearborn event .pdf published in the Lyme Disease Foundation’s journal:


1998 FDA Meeting where Luft says LYMErix produces a multi-system disease just like chronic Lyme:

BEN LUFT: "The point that I wanted to make in regard to the study is that there is very heavy dependence on serologic confirmation. And when we start thinking about the adverse events, *** it was stated originally when we got the overview of the disease that the disease is really quite protean [means not limited to "bad knees”- KMD]. And actually the adverse events are very similar to what the disease manifestations are.**** And if you start to, as I think Dr. Hall was eluding to -- if you start to kind of say well how often do you actually become sero positive, you can start to have a different take on when someone has an adverse event of whether it is disease specific or infection specific versus vaccine specific. And I think that that is an important issue that we have to deal with. I can only say from my own ..."


Evidence Lyme criminals knew LYMErix produced the same "multisystem disease" as "Chronic Lyme"

1) Ben Luft said it at the 1998 FDA meeting (above), 2) Dave Persing said it in his RICO patent (above), 3) Fish and Barbour started trashing us with their “Social Aspects” bullshit in 1993 (above) paving the way, claiming we’re all nuts and hysterics for when the vaccine produced the same result so they’d have a ready made derogatory slander/libel answer and propaganda,…

... 4) Dave Persing and his company Corixa wanted to sell vaccine adjuvants but they had to drop OspA as a candidate adjuvant because, he said… in another patent (applied for May, 2001 while LYMErix was still on the market, harming people and he never said anything to the FDA about it)…
“Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds”
"Accordingly, the methods of the invention provide a powerful and selective approach for modulating the innate immune response pathways in animals without giving rise to the toxicities often associated with the native bacterial components that normally stimulate those pathways.",800,613.PN.&OS=PN/6,800,613&RS=PN/6,800,613

5) In 1998 Robert Schoen (involved in developing the RICO monopoly patent - US 6,045,804 - with Dave Persing, 1995) wrote this, once again, paving the way for when the vaccine came on the market and caused the same systemic, seronegative disease damage…

says in 1998 not to test LYMErix victims and minimizes their symptoms knowing chronic Lyme is identical to what Schoen says is "nonspecific" because the exact reverse statement is in the Corixa-RICO patent "multisystem complaints characteristic of late Lyme",  This is that textbook:


Next, how these crooks lied about their vaccine results, and what happened after LYMErix was approved and on the market.


The 1998 Vaccines Reports (ImmuLyme and LYMErix):

LYMErix results (76% "safe and effective"):

ImmuLyme results (92% "safe and effective"): 

From the LYMErix trial, "categories of outcomes:"


Here the crooks claim "we can't read our OspA vaccine results" reports, which means the lied in their OspA vaccine safety and efficacy reports, since they both claimed to be using the Dearborn method and MarDx's Western Blot test strips:

1) SCHOEN and PERSING, with JOHN ANDERSON,1996 - the RICO report:

The Dave Persing, Mayo Clinic FRAUD Patent-6,045,804 

4) Yale's ROBERT SCHOEN in the 1998 Munchausen's Book, instructing MDs to blow off LYMErix systemically injured people ("but send the post-vaccination blood to the Yale L2 Diagnostics RICO lab if you must bother to be a physician").

This ▲ is obviously a FALSE CLAIM or a QUI TAM or FRAUD on the GOVERNMENT since they're declaring to the FDA, in the LYMErix case, saying they had a vaccine.


I'll just plagiarize myself here and just use the text from the reports below on "Lyme Facts" and "Borreliosis Basics":

So in the Fall of 1998, the LYMErix vaccine was approved, anyway, by the FDA (the FDA panel being loaded with people like Allen Steere, Robert Schoen, and Vijay Sikand – the very people who ran the OspA trials) and came on to the market in late 1998 despite numerous “provisos.” More than 1,000 systemic adverse events were reported through the VAERS from September 1999 to November 2000, whereupon the FDA granted a public hearing, January 31, 2001:

Whereupon I blew the whistle on Dearborn and how LYMErix actually caused immunosuppression (the FDA did not scan in the last 19 pages of this booklet, which were 19 pages out of the Dearborn booklet, proving no one agreed with Steere's proposal for an antibody panel for a "case definition":

Several months later, in the fall of 2001, Karen Forschner of the Hartford, CT based Lyme Disease Foundation ( delivered to the FDA – in person -, a patent owned by Bridgitte Huber at Tufts where it was declared that OspA was technically a “toxin,” right in the abstract (US Patent 6,689,384). The FDA then gave SmithKline and Yale (the assignee of the LYMErix patent), an ultimatum: “Either you remove LYMErix voluntarily or we will order it off the market.” SmithKline chose to avoid the embarrassment and pulled their own non-vaccine.

We’re still stuck with this bogus Dearborn case definition, despite numerous attempts at lawsuits against IDSA, SmithKline, and filing complaints to the U. S. Department of Justice. It is still very dangerous for the public to be unaware that the average person, or 85% of us – who are the “seronegative patients are the sickest ,“ according to Raymond Dattwyler at the 1994 FDA meeting on Lyme and LYMErix (which preceded Dearborn) - have no chance of testing positive to this criminal CDC’-Dearborn standard, because the actual disease is one of immunosuppression, or is an Acquired Immune Deficiency,… or is similar to AIDS with all the opportunistic infections that the Lyme and LYMErix victims cannot control.

It was said at the time LYMErix was still on the market that this vaccine, via its claimed mechanism of disinfecting ticks with human antibodies (yes, if you can believe it), that LYMErix would turn humans into walking cannisters of tick disinfectant, when in fact, LYMErix turned people into walking “cesspools of disease.” The same is true for Chronic Lyme. Chronic Lyme victims’ immune systems are “overwhelmed”- a term used by CDC officer Alan Barbour, when describing what antigenic variation in spirochetes does to humans (US Patent 6,719,983). This is a term you want to remember in case you hear it again: “overwhelmed” immune system means: “turned off.” “Turned off” is the complete opposite of an “inflammatory” or “autoimmune disease.”


That's all for now, folks.... KMD